(Q34163679)

English

Biological properties of androgen receptor pure antagonist for treatment of castration-resistant prostate cancer: optimization from lead compound to CH5137291.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Biological properties of androgen receptor pure antagonist for treatment of castration-resistant prostate cancer: optimization from lead compound to CH5137291. (English)

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

author name string

Hiromitsu Kawata

1

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Shinichi Arai

2

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Toshito Nakagawa

3

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Nobuyuki Ishikura

4

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Ayako Nishimoto

5

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Hitoshi Yoshino

6

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Takuya Shiraishi

7

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Kazutaka Tachibana

8

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Ryo Nakamura

9

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Haruhiko Sato

10

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

9 February 2011

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

71

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

1344-1356

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Cancer mortality in the European Union, 1970-2003, with a joinpoint analysis.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21351

21 January 2018

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21351

21 January 2018

Cancer incidence and incidence rates in Japan in 2002: based on data from 11 population-based cancer registries

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21351

21 January 2018

Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21351

21 January 2018

Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21351

21 January 2018

Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21351

21 January 2018

Evaluation of quality of life in patients with previously untreated advanced prostate cancer receiving maximum androgen blockade therapy or LHRHa monotherapy: a multicenter, randomized, double-blind, comparative study

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21351

21 January 2018

Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: a Southwest Oncology Group study (SWOG 9235).

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21351

21 January 2018

Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21351

21 January 2018

Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21351

21 January 2018

Castration-resistant prostate cancer: locking up the molecular escape routes

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21351

21 January 2018

Mechanisms underlying the development of androgen-independent prostate cancer.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21351

21 January 2018

Progress in understanding androgen-independent prostate cancer (AIPC): a review of potential endocrine-mediated mechanisms

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21351

21 January 2018

Short hairpin RNA knockdown of the androgen receptor attenuates ligand-independent activation and delays tumor progression

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21351

21 January 2018

Androgen receptor down regulation by small interference RNA induces cell growth inhibition in androgen sensitive as well as in androgen independent prostate cancer cells.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21351

21 January 2018

Small-interfering RNA-induced androgen receptor silencing leads to apoptotic cell death in prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21351

21 January 2018

Molecular determinants of resistance to antiandrogen therapy

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21351

21 January 2018

Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21351

21 January 2018

Prolonged treatment with bicalutamide induces androgen receptor overexpression and androgen hypersensitivity

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21351

21 January 2018

Structure-activity relationships of bioisosteric replacement of the carboxylic acid in novel androgen receptor pure antagonists

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21351

21 January 2018

Development of the VCaP androgen-independent model of prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21351

21 January 2018

Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21351

21 January 2018

In vivo amplification of the androgen receptor gene and progression of human prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21351

21 January 2018

Nuclear import of the human androgen receptor

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21351

21 January 2018

Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21351

21 January 2018

Androgen receptor localisation and turnover in human prostate epithelium treated with the antiandrogen, casodex.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21351

21 January 2018

Molecular biology of the androgen receptor

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21351

21 January 2018

Androgen receptor in prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21351

21 January 2018

Molecular chaperones throughout the life cycle of the androgen receptor

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21351

21 January 2018

Structural basis for the nuclear import of the human androgen receptor

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21351

21 January 2018

The hinge region regulates DNA binding, nuclear translocation, and transactivation of the androgen receptor

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21351

21 January 2018

Impaired nuclear translocation, nuclear matrix targeting, and intranuclear mobility of mutant androgen receptors carrying amino acid substitutions in the deoxyribonucleic acid-binding domain derived from androgen insensitivity syndrome patients

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21351

21 January 2018

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21351

21 January 2018

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21351

21 January 2018

Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21351

21 January 2018

Identifiers

10.1002/PROS.21351

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34163679&oldid=1980521037"